Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07607483 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4065967 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT07607483 is a Phase 1 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 36 participants.
The verdict
NCT07607483, a Phase 1 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare 3 different forms of LY4065967 - a tablet and 2 types of capsule - to see how much and how quickly each gets into the bloodstream after it is swallowed, and to check for any side effects. For each participant, the study will last about 7 weeks and will include 3 stays in the Clinical Research Unit (CRU). Each stay will last 3 nights.
Interventions
- DRUG LY4065967 Tablet
- DRUG LY4065967 Formulated Capsule
- DRUG LY4065967 Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-06-03 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07607483
The ClinicalTrials.gov registry entry for NCT07607483 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which LY4065967 Tablet is the first listed.
NCT07607483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07607483 about?
NCT07607483 is a clinical study titled "A Study of LY4065967 in Healthy Participants". The main purpose of this study is to compare 3 different forms of LY4065967 - a tablet and 2 types of capsule - to see how much and how quickly each gets into the bloodstream after it is swallowed, and to check for any side effects. For each participant, the study will last about 7 weeks and will in...
What is the current status of trial NCT07607483?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2026-06-03. Estimated completion is 2026-07.
What interventions are being tested in trial NCT07607483?
The interventions under investigation include: LY4065967 Tablet (DRUG), LY4065967 Formulated Capsule (DRUG), LY4065967 Capsule (DRUG).
Who is sponsoring clinical trial NCT07607483?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.